The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Maglione, M.
* Articles by Shekelle, P. G.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Maglione, M.
* Articles by Shekelle, P. G.
Related Collections
* Schizophrenia Spectrum Disorders
* Caffeine
* Other Somatic Therapy
Am J Psychiatry 162:189-191, January 2005
© 2005 American Psychiatric Association


Brief Report

Psychiatric Effects of Ephedra Use: An Analysis of Food and Drug Administration Reports of Adverse Events

Margaret Maglione, M.P.P., Karen Miotto, M.D., Martin Iguchi, Ph.D., Lara Jungvig, B.A., Sally C. Morton, Ph.D., and Paul G. Shekelle, M.D., Ph.D.

OBJECTIVE: As part of a synthesis of evidence regarding the efficacy and safety of ephedra, the authors describe data on psychiatric adverse events from reports submitted to the Food and Drug Administration (FDA). METHOD: The authors reviewed all 1,820 adverse event reports related to dietary supplements containing herbal ephedra from FDA MedWatch files as of Sept. 30, 2001. Fifty-seven serious psychiatric events were reported. RESULTS: The most commonly reported events were psychosis, severe depression, mania or agitation, hallucinations, sleep disturbance, and suicidal ideation. Ten events involved physical harm to self or others; five events resulted in legal action due to criminal behavior. Twenty-six events resulted in hospitalization, at least six of which were involuntary. Of importance, two-thirds of all cases involved patients with preexisting psychiatric conditions and /or use of other medications or illicit substances. CONCLUSIONS: Clinicians should be aware that serious psychiatric symptoms could be associated with ephedra use.




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
R. B Wallace, B. M Gryzlak, M B. Zimmerman, and N. L Nisly
Application of FDA Adverse Event Report Data to the Surveillance of Dietary Botanical Supplements
Ann. Pharmacother., May 1, 2008; 42(5): 653 - 660.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
S. C. MILLER
Psychiatric Effects of Ephedra: Addiction
Am J Psychiatry, November 1, 2005; 162(11): 2198 - 2198.
[Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org